Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	B:C0009253
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	B:C0040808
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	B:C0012634
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	B:C1299433
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	B:C0920317
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	B:C0087111
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	B:C1532338
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	B:C0038257
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	B:C0018821
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	B:C0087111
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	B:C1536078
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	B:C0162577
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	B:C1299433
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	B:C0087111
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	B:C1536078
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	B:C1322815
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	B:C0021107
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	B:C0087111
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	B:C0010068
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	O
Controlled	I:C0206035
Trials	I:C0206035

Geographical	O
Difference	O
of	O
the	O
Interaction	O
of	O
Sex	O
With	O
Treatment	O
Strategy	I:C0040808
in	O
Patients	O
With	O
Multivessel	O
Disease	I:C0012634
and	O
Left	O
Main	I:C1299433
Disease	I:C1299433
:	O
A	O
Meta-Analysis	O
From	O
SYNTAX	O
(	O
Synergy	O
Between	O
PCI	O
With	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
With	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
Randomized	B:C0206035
Controlled	I:C0206035
Trials	I:C0206035

The	O
impact	O
of	O
sex	B:C0009253
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	B:C0456984
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	B:C1532338
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	B:C0010068
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	B:C1299433
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	B:C1257890
and	O
Asian	O
populations	I:C0078988
.	O

The	O
impact	O
of	O
sex	O
on	O
clinical	O
outcomes	I:C0456984
of	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
and	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
for	O
patients	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
could	O
be	O
dissimilar	O
between	O
Western	O
and	O
Asian	B:C0078988
populations	I:C0078988
.	O

To	O
assess	O
clinical	B:C0456984
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	B:C1532338
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	B:C0043210
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	B:C0025266
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	B:C0010068
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	B:C1299433
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	B:C0936012
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	B:C0206035
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	B:C0087111
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	B:C1532338
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	B:C0038257
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	B:C0018821
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	B:C0087111
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	B:C1536078
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	B:C0162577
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	B:C1299433
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	B:C0087111
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	B:C1536078
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	B:C1322815
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	B:C0021107
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	B:C0087111
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	B:C0010068
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	O
.	O

To	O
assess	O
clinical	O
outcomes	I:C0456984
after	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
or	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
in	O
women	O
and	O
men	O
with	O
multivessel	O
coronary	I:C0010068
disease	I:C0010068
and	O
unprotected	O
left	O
main	I:C1299433
disease	I:C1299433
,	O
a	O
pooled	O
analysis	I:C0936012
(	O
n=3280	O
)	O
was	O
performed	O
using	O
the	O
patient	O
-	O
level	O
data	O
from	O
3	O
large	O
randomized	O
trials	I:C0206035
:	O
SYNTAX	O
(	O
Synergy	O
between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
)	O
,	O
PRECOMBAT	O
(	O
Bypass	O
Surgery	I:C1536078
Versus	O
Angioplasty	O
Using	O
Sirolimus	O
-	O
Eluting	O
Stent	O
in	O
Patients	O
With	O
Left	O
Main	I:C1299433
Coronary	I:C1299433
Artery	I:C1299433
Disease	I:C1299433
)	O
,	O
and	O
BEST	O
(	O
Bypass	O
Surgery	I:C1536078
and	O
Everolimus	O
-	I:C1322815
Eluting	I:C1322815
Stent	I:C1322815
Implantation	O
in	O
the	O
Treatment	O
of	O
Patients	O
with	O
Multivessel	O
Coronary	I:C0010068
Artery	I:C0010068
Disease	I:C0010068
)	O
trials	B:C0206035
.	O

The	O
primary	O
end	O
point	O
was	O
all	B:C0007465
-	I:C0007465
cause	I:C0007465
death	I:C0007465
.	O

Of	O
3280	O
patients	O
,	O
794	O
patients	O
(	O
24.2	O
%	O
)	O
were	O
women	B:C0043210
.	O

The	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
period	O
was	O
1806	O
days	O
(	O
1611	O
-	O
1837	O
days	O
)	O
.	O

In	O
women	B:C0043210
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	O
effect	I:C1518681
among	O
the	O
3	O
trials	O
was	O
found	O
for	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	O
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	O
.	O

In	O
women	O
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	B:C1518681
effect	I:C1518681
among	O
the	O
3	O
trials	O
was	O
found	O
for	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	O
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	O
.	O

In	O
women	O
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	O
effect	I:C1518681
among	O
the	O
3	O
trials	B:C0206035
was	O
found	O
for	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	O
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	O
.	O

In	O
women	O
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	O
effect	I:C1518681
among	O
the	O
3	O
trials	O
was	O
found	B:C0150312
for	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	O
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	O
.	O

In	O
women	O
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	O
effect	I:C1518681
among	O
the	O
3	O
trials	O
was	O
found	O
for	O
all	B:C0007465
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	O
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	O
.	O

In	O
women	O
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	O
effect	I:C1518681
among	O
the	O
3	O
trials	O
was	O
found	O
for	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	B:C0025266
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	O
.	O

In	O
women	O
,	O
a	O
high	O
heterogeneity	O
of	O
the	O
treatment	O
effect	I:C1518681
among	O
the	O
3	O
trials	O
was	O
found	O
for	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
(	O
I	O
(	O
2	O
)	O
>	O
50	O
%	O
)	O
,	O
whereas	O
in	O
men	O
,	O
it	O
was	O
consistent	O
across	O
the	O
3	O
trials	B:C0206035
.	O

In	O
the	O
Western	B:C1257890
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	B:C0206035
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	B:C0087111
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	B:C0043210
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	B:C0009253
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	B:C1532338
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	B:C1532338
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	B:C0078988
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	B:C0043210
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	B:C0087111
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	B:C0087111
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	B:C0087111
effect	O
was	O
neutral	O
between	O
both	O
strategies	O
.	O

In	O
the	O
Western	O
trial	O
(	O
SYNTAX	O
)	O
,	O
female	O
sex	O
favored	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
compared	O
with	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
(	O
hazard	O
ratio	O
(	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
)	O
2.213	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.242-3.943	O
;	O
P=0.007	O
)	O
,	O
whereas	O
in	O
the	O
Asian	O
women	O
(	O
PRECOMBAT	O
and	O
BEST	O
)	O
,	O
the	O
treatment	O
effect	O
was	O
neutral	O
between	O
both	O
strategies	B:C0040808
.	O

Sex	B:C0009253
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	O
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	B:C0040808
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	O
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	B:C1257890
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	O
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	B:C0206035
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	O
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	B:C0078988
trials	O
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	B:C0206035
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	O
(	O
PRECOMBAT	B:C0087111
Pinteraction	O
=0.469	O
and	O
BEST	O
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

Sex	O
interaction	O
with	O
treatment	O
strategy	I:C0040808
was	O
evident	O
in	O
the	O
Western	O
trial	O
(	O
Pinteraction	O
=0.019	O
)	O
but	O
not	O
in	O
the	O
Asian	O
trials	O
(	O
PRECOMBAT	O
Pinteraction	O
=0.469	O
and	O
BEST	B:C0087111
Pinteraction	O
=	O
0.472	O
;	O
I	O
(	O
2)=58	O
%	O
)	O
.	O

The	O
present	O
meta-analysis	B:C0920317
suggested	O
the	O
presence	O
of	O
the	O
heterogeneous	O
sex	O
-	O
treatment	O
interaction	O
across	O
Asian	O
and	O
Western	O
trials	O
.	O

The	O
present	O
meta-analysis	O
suggested	O
the	O
presence	B:C0150312
of	O
the	O
heterogeneous	O
sex	O
-	O
treatment	O
interaction	O
across	O
Asian	O
and	O
Western	O
trials	O
.	O

The	O
present	O
meta-analysis	O
suggested	O
the	O
presence	O
of	O
the	O
heterogeneous	O
sex	B:C0009253
-	O
treatment	O
interaction	O
across	O
Asian	O
and	O
Western	O
trials	O
.	O

The	O
present	O
meta-analysis	O
suggested	O
the	O
presence	O
of	O
the	O
heterogeneous	O
sex	O
-	O
treatment	B:C0087111
interaction	O
across	O
Asian	O
and	O
Western	O
trials	O
.	O

The	O
present	O
meta-analysis	O
suggested	O
the	O
presence	O
of	O
the	O
heterogeneous	O
sex	O
-	O
treatment	O
interaction	O
across	O
Asian	B:C0078988
and	O
Western	O
trials	O
.	O

The	O
present	O
meta-analysis	O
suggested	O
the	O
presence	O
of	O
the	O
heterogeneous	O
sex	O
-	O
treatment	O
interaction	O
across	O
Asian	O
and	O
Western	B:C1257890
trials	O
.	O

The	O
present	O
meta-analysis	O
suggested	O
the	O
presence	O
of	O
the	O
heterogeneous	O
sex	O
-	O
treatment	O
interaction	O
across	O
Asian	O
and	O
Western	O
trials	B:C0206035
.	O

Considering	O
the	O
ongoing	O
globalization	O
of	O
our	O
medical	B:C0032895
practice	I:C0032895
,	O
the	O
heterogeneity	O
of	O
the	O
sex	O
-	O
treatment	O
interaction	O
needs	O
to	O
be	O
well	O
recognized	O
and	O
taken	O
into	O
account	O
during	O
the	O
decision	O
making	I:C0011109
of	O
the	O
treatment	O
strategy	I:C0040808
.	O

Considering	O
the	O
ongoing	O
globalization	O
of	O
our	O
medical	O
practice	I:C0032895
,	O
the	O
heterogeneity	O
of	O
the	O
sex	B:C0009253
-	O
treatment	O
interaction	O
needs	O
to	O
be	O
well	O
recognized	O
and	O
taken	O
into	O
account	O
during	O
the	O
decision	O
making	I:C0011109
of	O
the	O
treatment	O
strategy	I:C0040808
.	O

Considering	O
the	O
ongoing	O
globalization	O
of	O
our	O
medical	O
practice	I:C0032895
,	O
the	O
heterogeneity	O
of	O
the	O
sex	O
-	O
treatment	B:C0087111
interaction	O
needs	O
to	O
be	O
well	O
recognized	O
and	O
taken	O
into	O
account	O
during	O
the	O
decision	O
making	I:C0011109
of	O
the	O
treatment	O
strategy	I:C0040808
.	O

Considering	O
the	O
ongoing	O
globalization	O
of	O
our	O
medical	O
practice	I:C0032895
,	O
the	O
heterogeneity	O
of	O
the	O
sex	O
-	O
treatment	O
interaction	O
needs	O
to	O
be	O
well	O
recognized	O
and	O
taken	O
into	O
account	O
during	O
the	O
decision	B:C0011109
making	I:C0011109
of	O
the	O
treatment	O
strategy	I:C0040808
.	O

Considering	O
the	O
ongoing	O
globalization	O
of	O
our	O
medical	O
practice	I:C0032895
,	O
the	O
heterogeneity	O
of	O
the	O
sex	O
-	O
treatment	O
interaction	O
needs	O
to	O
be	O
well	O
recognized	O
and	O
taken	O
into	O
account	O
during	O
the	O
decision	O
making	I:C0011109
of	O
the	O
treatment	B:C0040808
strategy	I:C0040808
.	O

